Sanofi's Q1 even worse than feared
This article was originally published in Scrip
Sanofi has reported a first quarter even poorer than forecast, with sales down 3%. 2013 is the year Sanofi will feel worst effects of its patent cliff, particularly in the US. Analysts had expected sales to drop by around 1% (scripintelligence.com, 30 April 2013).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.